On November 29, 2022, AcelRx Pharmaceuticals, Inc. received notice from Patheon Pharmaceuticals Inc. that it intends to terminate the Manufacturing Services Agreement between the parties, effective December 12, 2012, as amended January 19, 2016 and August 4, 2017. The term of the MSA automatically renews for successive two-year terms unless one of the parties gives 18 months' notice that it does not intend to renew the MSA. Based on Patheon's date of notice, the MSA will terminate on May 31, 2024.

Patheon will continue to supply product under the MSA until the Termination Date. The Company expects to discuss a transition plan with Patheon in the near future. The Company and Patheon also entered into an Amended and Restated Capital Expenditure and Equipment Agreement effective December 12, 2012, as amended July 26, 2013, and January 30, 2014 which, under Section 8(a) of the Capital Agreement, terminates upon termination of the MSA.